Investment Rating - The investment rating for the company is "Accumulate" (maintained) [2] Core Views - The company reported strong performance in Q3 with revenue of 14.557 billion yuan, a year-on-year increase of 20.85%, and a net profit of 590 million yuan, up 24.02% year-on-year [7][8] - The company has a future action plan to distribute at least 70% of the annual net profit in cash or a minimum of 400 million yuan (including tax) as dividends, which translates to a current dividend yield of 4.8%, indicating significant investment attractiveness [7][8] - The company has optimized its order structure with a notable increase in overseas contracts, which accounted for 27.8% of total orders in the first three quarters of 2025, up from 13.7% in 2024 [7][8] Financial Performance - For the first three quarters of 2025, the company achieved steel structure sales of 1.18 million tons, a year-on-year increase of 34.6% [7][8] - The company’s revenue projections for 2025-2027 are 23.836 billion yuan, 28.335 billion yuan, and 32.490 billion yuan, respectively, with net profits expected to be 640 million yuan, 733 million yuan, and 838 million yuan [6][8] - The company’s PE ratios based on the closing price on October 28 are projected to be 13.0, 11.3, and 9.9 for 2025, 2026, and 2027, respectively [6][8] Cash Flow and Profitability - The operating cash flow for the first three quarters was 761 million yuan, an increase of 533 million yuan year-on-year, with a cash collection ratio of 112.06% [8] - The gross profit margin for the first three quarters was 11.52%, a decrease of 1.54 percentage points year-on-year, while the net profit margin was 4.05%, showing a slight increase [8] Order and Market Expansion - The company signed new contracts worth 17.6 billion yuan in EPC and 11.4 billion yuan in prefabricated/industrial chain and strategic franchise/BIPV businesses, with significant growth in the latter two areas [7][8] - The overseas business has expanded into six major regional markets, effectively mitigating the impact of intense competition in the domestic construction market [7][8]

Reported Industry Investment Rating - Not provided in the content Core Views of the Report - As of 3Q2025, there were 4,456 active equity funds in the market, an increase of 71 from the end of the previous quarter, with a total fund size of 3.79 trillion yuan [3][8]. - In 3Q2025, the equity positions of common stock - type, partial - stock hybrid, and flexible allocation funds increased slightly, and the positions in the Hong Kong stock market continued to rise. The equity positions were 90.89%, 89.02%, and 74.76% respectively, up 0.69 pct, 1.53 pct, and 2.19 pct from the end of the previous quarter. The Hong Kong stock positions were 12.93%, 17.37%, and 4.09% respectively, up 0.08 pct, 0.26 pct, and 0.01 pct from the end of the previous quarter [3]. - The concentration of individual stocks and industries increased slightly. The concentrations of the top three, top five, and top ten individual stocks were 21.98%, 33.04%, and 53.75% respectively, up 0.90 pct, 1.38 pct, and 1.84 pct from the end of the previous quarter. The concentrations of the first, top three, and top five industries were 24.47%, 41.76%, and 49.64% respectively, up 1.54 pct, 2.38 pct, and 2.51 pct from the end of the previous quarter [3]. - In terms of heavy - position sectors, in A - share market, the heavy - position stocks of active equity funds increased their positions in the technology sector by 11.36 pct compared with the previous quarter. In the Hong Kong stock market, the heavy - position stocks increased their positions in the consumer and pharmaceutical sectors by 3.23 pct and 2.37 pct respectively compared with the previous quarter [3]. - In terms of A - share allocation in 3Q2025, the top three industries in terms of market value of heavy - position stocks of active equity funds were electronics, power equipment and new energy, and pharmaceuticals, accounting for 23.01%, 10.32%, and 10.09% respectively. The top three industries with the largest active increase in positions were communication, computer, and electronics, with increases of 2.77 pct, 2.00 pct, and 1.79 pct respectively [3]. - In terms of Hong Kong stock allocation in 3Q2025, the top three industries in terms of market value of heavy - position stocks of active equity funds were media, pharmaceuticals, and commerce and retail, accounting for 22.69%, 15.79%, and 13.58% respectively. The top three industries with the largest active increase in positions were commerce and retail, pharmaceuticals, and electronics, with increases of 4.80 pct, 1.34 pct, and 1.00 pct respectively [3]. - In 3Q2025, the top three A - shares with the largest active increase in positions compared with the end of the previous quarter were Industrial and Commercial Bank of China, Shennan Circuit, and Zhongji Innolight, with increases of 282.41 billion yuan, 77.17 billion yuan, and 71.51 billion yuan respectively. The top three Hong Kong stocks with the largest active increase in positions were Alibaba - W, Huahong Semiconductor, and Jiufang Zhitou Holdings, with increases of 170.28 billion yuan, 26.99 billion yuan, and 18.13 billion yuan respectively [3]. Summary by Relevant Catalogs 1. Scale and Quantity Analysis - As of 3Q2025, the scale of active equity funds increased. There were 4,456 active equity funds in the market, an increase of 71 from the end of the previous quarter. The total scale was 3.79 trillion yuan, an increase of 619.566 billion yuan or 19.54% from the end of the previous quarter [8]. - The fund issuance market was hot. In 3Q2025, 111 new active equity funds were established, with a combined issuance share of 5.611 billion shares, a 53.33% increase from the end of the previous quarter [9]. - In terms of fund scale distribution, in 3Q2025, the proportion of active equity funds with a scale of less than 100 million yuan was 77.96%. The proportion of funds with a scale of less than 200 million yuan decreased by 3.58 pct, while the proportions of funds with scales of 200 - 1000 million yuan, 1000 - 5000 million yuan, 5000 - 10000 million yuan, and over 10000 million yuan increased by 0.98 pct, 1.78 pct, 0.60 pct, and 0.22 pct respectively [13]. 2. Position Analysis - In 3Q2025, the stock positions of active equity funds increased. The equity positions of common stock - type, partial - stock hybrid, and flexible allocation funds were 90.89%, 89.02%, and 74.76% respectively, up 0.69 pct, 1.53 pct, and 2.19 pct from the end of the previous quarter. These positions were at relatively high historical levels [16]. - The Hong Kong stock positions of active equity funds increased slightly. The Hong Kong stock positions of common stock - type, partial - stock hybrid, and flexible allocation funds were 12.93%, 17.37%, and 4.09% respectively, up 0.08 pct, 0.26 pct, and 0.01 pct from the end of the previous quarter. The number of funds allocating to Hong Kong stocks also increased [17]. 3. Heavy - Position Stock Concentration Analysis - In 3Q2025, the concentration of individual stocks and industries in active equity funds increased. The concentrations of the top three, top five, and top ten individual stocks were 21.98%, 33.04%, and 53.75% respectively, up 0.90 pct, 1.38 pct, and 1.84 pct from the end of the previous quarter. The concentrations of the first, top three, and top five industries were 24.47%, 41.76%, and 49.64% respectively, up 1.54 pct, 2.38 pct, and 2.51 pct from the end of the previous quarter, indicating an increase in risk preference [20]. 4. Heavy - Position Stock Sector Analysis - In the A - share market in 3Q2025, the top three sectors in terms of heavy - position stock allocation of active equity funds were technology, manufacturing, and cyclical sectors, accounting for 39.33%, 23.35%, and 13.58% respectively. The technology sector saw an increase in positions, while the consumer, financial real - estate, pharmaceutical, cyclical, and manufacturing sectors saw a decrease in positions [24]. - In the Hong Kong stock market in 3Q2025, the top three sectors in terms of heavy - position stock allocation of active equity funds were technology, consumer, and pharmaceutical sectors, accounting for 41.25%, 17.70%, and 15.79% respectively. The consumer, pharmaceutical, and cyclical sectors saw an increase in positions, while the technology, manufacturing, and financial real - estate sectors saw a decrease in positions [28]. 5. Heavy - Position Stock Industry Analysis 5.1 Active Equity Fund Heavy - Position Stock Industry Analysis - In A - share allocation in 3Q2025, the top three industries in terms of market value of heavy - position stocks of active equity funds were electronics, power equipment and new energy, and pharmaceuticals, accounting for 23.01%, 10.32%, and 10.09% respectively. The top three industries with the largest active increase in positions were communication, computer, and electronics, while the top three industries with the largest active decrease in positions were banking, home appliances, and national defense and military industry [30][32][33]. - In Hong Kong stock allocation in 3Q2025, the top three industries in terms of market value of heavy - position stocks of active equity funds were media, pharmaceuticals, and commerce and retail, accounting for 22.69%, 15.79%, and 13.58% respectively. The top three industries with the largest active increase in positions were commerce and retail, pharmaceuticals, and electronics, while the top three industries with the largest active decrease in positions were media, consumer services, and communication [36][37]. 5.2 Performance - Excellent and Hundred - Billion Fund Heavy - Position Stock Industry Analysis - In A - share allocation in 3Q2025, the top three industries in terms of market value of heavy - position stocks of performance - excellent funds were electronics, communication, and computer, accounting for 41.21%, 38.05%, and 8.45% respectively. The top three industries with the largest active increase in positions were computer, machinery, and automobile, while the top three industries with the largest active decrease in positions were electronics, media, and power equipment and new energy [40]. - The top three industries in terms of market value of heavy - position stocks of hundred - billion funds were electronics, pharmaceuticals, and food and beverage, accounting for 21.86%, 16.77%, and 13.12% respectively. The top three industries with the largest active increase in positions were communication, computer, and basic chemicals, while the top three industries with the largest active decrease in positions were transportation, electronics, and pharmaceuticals [40][41]. - In Hong Kong stock allocation in 3Q2025, the top three industries in terms of market value of heavy - position stocks of performance - excellent funds were commerce and retail, media, and electronics, accounting for 34.84%, 34.56%, and 24.14% respectively. The top three industries with the largest active increase in positions were commerce and retail, comprehensive finance, and non - ferrous metals, while the top three industries with the largest active decrease in positions were communication, home appliances, and pharmaceuticals [43]. - The top three industries in terms of market value of heavy - position stocks of hundred - billion funds were media, commerce and retail, and pharmaceuticals, accounting for 26.93%, 17.75%, and 12.36% respectively. The top three industries with the largest active increase in positions were commerce and retail, electronics, and pharmaceuticals, while the top three industries with the largest active decrease in positions were media, communication, and consumer services [43]. 6. Heavy - Position Individual Stock Analysis 6.1 Heavy - Position Individual Stock Market Value Analysis - In 3Q2025, the top three A - shares in terms of absolute market value of heavy - position allocation of active equity funds were CATL, Xinyisheng, and Zhongji Innolight, with market values of 67.31 billion yuan, 53.801 billion yuan, and 49.594 billion yuan respectively. The top three A - shares in terms of allocation market value ratio were Novartis Pharma - U, Aerospace South Lake, and Baili Tianheng, with the proportion of shares held accounting for 24.37%, 23.43%, and 23.29% of the tradable shares respectively [46]. - The top three Hong Kong stocks in terms of absolute market value of heavy - position allocation of active equity funds were Tencent Holdings, Alibaba - W, and SMIC, with market values of 65.575 billion yuan, 47.603 billion yuan, and 26.714 billion yuan respectively. The top three Hong Kong stocks in terms of allocation market value ratio were Sino Biopharm, Goldwind Science & Technology, and Kelun Botai Biopharm - B, with the proportion of shares held accounting for 11.75%, 10.73%, and 10.04% of the tradable shares respectively [47]. 6.2 Heavy - Position Individual Stock Active Position - Adjustment Analysis - In 3Q2025, the top three A - shares with the largest active increase in positions of active equity funds compared with the end of the previous quarter were Industrial and Commercial Bank of China, Shennan Circuit, and Zhongji Innolight, with increases of 28.241 billion yuan, 7.717 billion yuan, and 7.151 billion yuan respectively. The top three A - shares with the largest active decrease in positions were Shenghong Technology, Midea Group, and CATL, with decreases of 14.111 billion yuan, 7.982 billion yuan, and 7.262 billion yuan respectively [50]. - The top three Hong Kong stocks with the largest active increase in positions of active equity funds compared with the end of the previous quarter were Alibaba - W, Huahong Semiconductor, and Jiufang Zhitou Holdings, with increases of 17.028 billion yuan, 2.699 billion yuan, and 1.813 billion yuan respectively. The top three Hong Kong stocks with the largest active decrease in positions were Tencent Holdings, Xiaomi Group - W, and Meituan - W, with decreases of 7.926 billion yuan, 7.612 billion yuan, and 5.077 billion yuan respectively [52].

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [2] Core Views - The company is experiencing a decline in revenue and net profit due to weak demand and intense competition, but it is maintaining a high-end positioning to stabilize retail product prices [8] - The company is expected to see a recovery in profitability in the upcoming quarters as the competitive landscape improves and cost control measures take effect [8] - The forecasted net profit for 2025-2027 is projected to be 864 million, 969 million, and 1.074 billion yuan respectively, with corresponding EPS of 0.54, 0.61, and 0.67 yuan [8] Financial Performance Summary - Revenue for 2023 is projected at 6,378 million yuan, with a decline of 8.27% year-on-year, and is expected to further decline to 6,267 million yuan in 2024 and 6,006 million yuan in 2025 [7][9] - The net profit for 2023 is estimated at 1,432 million yuan, with a significant drop of 33.49% in 2024 to 953 million yuan, followed by a slight recovery to 864 million yuan in 2025 [7][9] - The company's gross margin is expected to stabilize at around 40.6% in 2025, with a slight improvement in operating cash flow [8][9] Market Performance - The company's stock has underperformed compared to the market, with a decline of 31% over the past 12 months [4]

Group 1: Economic Development Strategy - The Central Committee released suggestions for the 15th Five-Year Plan, focusing on optimizing traditional industries and fostering emerging sectors[1] - Emphasis on transforming manufacturing into intelligent, green, and integrated systems, aiming for a modern industrial framework led by advanced manufacturing[1] - Anticipated growth in high-end industries such as aerospace, low-altitude economy, and new materials, while addressing overcapacity[1] Group 2: Technological Innovation - The plan highlights the need for original innovation and tackling key core technologies, promoting deep integration of technology and industry[1] - Expected breakthroughs in critical areas like integrated circuits and foundational software during the 15th Five-Year period[1] - AI is projected to permeate various sectors, enhancing productivity and driving industrial evolution through a positive feedback loop[1] Group 3: Social Welfare and Employment - The strategy aims to ensure high-quality employment and improve income distribution, education, and social security systems[1] - Focus on developing a comprehensive service system for the elderly and children, including childcare subsidies and enhanced elderly care services[1] - The "silver economy" is expected to grow, driven by long-term care insurance and smart elderly care solutions[1] Group 4: Investment Recommendations - Investment focus on high-end manufacturing sectors like embodied intelligence and brain-computer interfaces, targeting leading companies with strong industrial capabilities[1] - In technology innovation, attention should be on emerging fields like AI Agents, emphasizing firms with core algorithms and ecosystem potential[1] - For the silver economy, recommend institutions involved in long-term care insurance and providers of smart elderly care solutions[1] Group 5: Risk Factors - Potential risks include slower-than-expected policy progress, economic growth below forecasts, escalating geopolitical conflicts, and challenges in technology commercialization[1]

Core Insights - The report maintains a positive outlook on the defense and military industry, highlighting recent performance and valuation metrics [2][4] - The defense and military industry index has shown a weekly increase of 2.81%, ranking 12th out of 31 in the Shenwan first-level industry classification [8][12] - The current PE-TTM for the defense and military industry is 85.77, which is in the 78.19th percentile of the past decade, indicating a relatively high valuation [14][15] Industry and Stock Performance Review Industry Performance Review - Over the past week (October 18-25, 2025), the defense and military industry index increased by 2.81%, ranking 12th among 31 Shenwan first-level industries [8] - In the past month (September 25 - October 25, 2025), the index saw a minimal change of 0.02%, ranking 17th [9] - Over the past year (October 25, 2024 - October 25, 2025), the index increased by 12.18%, ranking 19th [14] Stock Performance Review - The top-performing stocks in the defense and military sector over the past week include: - Aowei Communication (21.31%) - Feiliwa (17.92%) - Xingwang Yuda (15.29%) [19] - Conversely, the worst-performing stocks include: - Hangfa Control (-1.44%) - Qiyi Er (-1.60%) - Guorui Technology (-1.89%) [19] Funding Situation - The total transaction volume for the defense and military industry was 242.1 billion yuan for the week of October 18-25, 2025, which is a decrease of 43.00% year-on-year and a decrease of 22.10% week-on-week [30] - The military ETF fund shares decreased by 0.42% compared to the previous week but increased by 64.28% year-on-year [32] Important Company Announcements - Companies such as Aerospace Rainbow reported a 162.48% increase in revenue year-on-year for Q3 2025, while Guorui Technology reported a 6.98% decrease in revenue [36] - Notable increases in net profit were reported by companies like Zhenlei Technology (337.49% increase) and Sanjiao Defense (466.32% increase) [36] Industry News - Significant developments include the completion of the first phase of the Zhuque-3 rocket flight test and the launch of over 10,000 Starlink satellites [4]

3Q 海外业务承压，内销延续较快增长 佩蒂股份(300673) 1. 《2Q 海外业务暂承压，盈利能力持续提 升》 2025-08-27 2. 《2024 年业绩同比大幅增长，爵宴品牌 维持高增》 2025-01-22 3. 《Q3 归母净利同比大幅高增，自主品牌 保持增长》 2024-10-23 核心观点 盈利预测 | [币种Table_FinchinaSimple] (人民币) | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业收入(百万元) | 1,411 | 1,659 | 1,707 | 2,047 | 2,291 | | 收入增长率(%) | -18.5 | 17.6 | 2.9 | 19.9 | 11.9 | | 归母净利润(百万元) | -11 | 182 | 164 | 219 | 267 | | 净利润增长率(%) | -108.7 | — | -10.0 | 33.9 | 21.9 | | EPS(元) | -0.04 | 0.75 | 0.66 | 0.88 | 1.0 ...

计提影响业绩，静待提价效果显现 北新建材(000786) 证券研究报告 装修建材 / 公司点评 / 2025.10.28 投资评级:增持(维持) | 基本数据 | 2025-10-27 | | --- | --- | | 收盘价(元) | 23.65 | | 流通股本(亿股) | 16.35 | | 每股净资产(元) | 15.78 | | 总股本(亿股) | 17.00 | 最近 12 月市场表现 -24% -15% -6% 3% 12% 20% 北新建材 沪深300 上证指数 装修建材 分析师 毕春晖 SAC 证书编号：S0160522070001 bich@ctsec.com 分析师 陈琳云 SAC 证书编号：S0160524120005 chenly03@ctsec.com 相关报告 1. 《石膏板收入承压，两翼业务稳健》 2025-08-19 2. 《稳字当头，高基数下收入利润双增》 2025-04-25 3. 《Q4 石膏板略有承压，费用影响业绩增 速》 2025-03-27 核心观点 盈利预测 | [币种Table_FinchinaSimple] (人民币) | 2023A | 2024A | ...

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [2] Core Views - The company has experienced a rebound in chick prices, leading to a recovery in profitability, with continued growth in the sales of chick breeds and breeding pigs [1][4] - The company reported a revenue of 2.036 billion yuan for the first three quarters, a decrease of 5.44% year-on-year, and a net profit of 32 million yuan, down 89.42% year-on-year [7] - The sales volume of white feather chicks continued to grow, with a total of 490 million chicks sold in the first three quarters, an increase of 13.3% year-on-year [7] - The company has solid competitive advantages in breeding supply, with a significant increase in breeding pig sales [7] - The forecast for revenue from 2025 to 2027 is 3.385 billion yuan, 3.947 billion yuan, and 4.509 billion yuan respectively, with net profits expected to be 121 million yuan, 308 million yuan, and 588 million yuan [7][8] Financial Performance Summary - Revenue for 2023 is projected at 3.225 billion yuan, with a growth rate of 52.7% [5] - The net profit for 2023 is expected to be 541 million yuan, with an EPS of 0.54 yuan [5] - The PE ratio for 2025 is projected to be 83.7, decreasing to 17.3 by 2027 [5] - The company’s return on equity (ROE) is expected to be 2.9% in 2025, improving to 13.0% by 2027 [5][8]

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [2] Core Views - The company has shown a positive revenue growth in Q3 2025, driven by new product launches such as jelly wine and light enjoyment series, alongside the gradual market entry of its whiskey business [7] - The report anticipates that the company will achieve revenue of 30.7 billion, 35.25 billion, and 40.5 billion RMB for the years 2025, 2026, and 2027 respectively, with corresponding net profits of 7.09 billion, 8.53 billion, and 9.78 billion RMB [7] Financial Performance Summary - For the first three quarters of 2025, the company reported revenue of 2.27 billion RMB, a year-on-year decrease of 4.89%, and a net profit of 549 million RMB, down 4.35% year-on-year [7] - In Q3 2025, revenue reached 781 million RMB, reflecting a year-on-year increase of 2.99%, while net profit was 160 million RMB, a decrease of 6.76% year-on-year [7] - The company's sales net profit margin in Q3 2025 was 20.52%, down 2.15 percentage points year-on-year, attributed to increased sales expenses and a rise in tax rates [7] Earnings Forecast - The projected earnings for the company are as follows: - Revenue (in million RMB): 3,070 (2025E), 3,525 (2026E), 4,050 (2027E) - Net profit (in million RMB): 709 (2025E), 853 (2026E), 978 (2027E) - EPS (in RMB): 0.68 (2025E), 0.81 (2026E), 0.93 (2027E) - PE ratios: 40.3 (2025E), 33.5 (2026E), 29.2 (2027E) [6][8]

Core Insights - The report emphasizes the significant role of phosphoramidite monomers in the small nucleic acid industry chain, highlighting their impact on the development of small nucleic acid drugs, which are considered promising candidates for treating various diseases due to their unique molecular structures and therapeutic mechanisms [1][6][10] - The report predicts robust growth in the demand for phosphoramidite monomers, with multinational pharmaceutical companies likely to benefit from this trend, as the global nucleotide market is projected to reach USD 730 million in 2023, with China being the largest production market [10][11] Section Summaries Phosphoramidite Monomer's Role - Phosphoramidite monomers are crucial raw materials for synthesizing small nucleic acid drugs, enhancing their stability and biological activity, and driving innovation in drug development [6][9] - The solid-phase phosphoramidite method is the mainstream technique for synthesizing oligonucleotides, which are a major cost component in nucleic acid drug production [9] Market Dynamics - The report notes that 90% of global nucleotides are used for nucleic acid drug production, with only about 10% allocated to health foods and agriculture [10] - The small nucleic acid drug market is primarily dependent on major multinational pharmaceutical companies, indicating potential benefits for companies within their supply chains [11] Investment Recommendations - The report suggests focusing on innovative drug companies such as Furuya Co., OncoOne, and others, as well as raw material suppliers like WuXi AppTec and others, indicating a diverse range of investment opportunities in the sector [10]